Masakazu Fujio
Mitsubishi
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Masakazu Fujio.
Nuclear Medicine and Biology | 2002
Masakazu Fujio; Shinji Nagata; Kazunori Kawamura; Naoki Sugiyama; Hiroshi Tanaka; Kimiichi Uno; Kiichi Ishiwata
Abstract We prepared 5-HT 1A receptor ligands ( S )- N -{[1-(2-phenylethyl)pyrrolidin-2-yl]methyl}-3-[ 11 C]methylthiobenzamide ([ 11 C]( S )-PPMMB) (Ki = 4.3 nM) and the less active [ 11 C]( R )-PPMMB (Ki = 160 nM) by reduction of the disulfide dimer and subsequent [ 11 C]methylation of demethyl ( S )- and ( R )-PPMMB, respectively. Both radioligands showed similar brain distribution in mice with relatively higher affinity for the hippocampus being rich in 5-HT 1A receptors than for other brain regions. Uptake of [ 11 C]( S )-PPMMB was not reduced by carrier-loading nor by pretreatment with 5-HT 1A receptor ligands. [ 11 C]( S )-PPMMB is therefore not a suitable radioligand for mapping 5-HT 1A receptors using positron emission tomography.
Bioorganic & Medicinal Chemistry Letters | 2000
Masakazu Fujio; Takanobu Kuroita; Yoko Sakai; Haruto Nakagawa; Yasuhiro Matsumoto
A series of 1-adamantanecarboxamides was synthesized and examined for their potency as a selective 5-HT2 receptor antagonist. We found (S)-N-[1-[2-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-1-adamantane carboxamide hydrochloride hydrate (10-(S), Y-39241) to have a high affinity and selectivity for 5-HT2 receptors, and this potent anti-platelet effect of Y-39241 was confirmed both in vitro and in vivo.
Bioorganic & Medicinal Chemistry Letters | 2000
Masakazu Fujio; Yoshifumi Togo; Hideo Tomozane; Takanobu Kuroita; Yasunori Morio; Jiro Katayama; Yasuhiro Matsumoto
A series of benzamides was synthesized as selective agonists for the 5-HT1A receptor. It was found that (S)-N-[[1-(2-phenylethyl)pyrrolidin-2-yl]methyl]cyclohexanecarb oxamide(7-(S)) has potent and selective agonistic activity for the 5-HT1A receptor (5-HT1A; Ki 0.49 nmol/L, D2; IC50 = >1000 nmol/L, 5-HT2; Ki = 240 nmol/L).
Archive | 2002
Masakazu Fujio; Hiroyuki Satoh; Atsushi Numata; Shinichi Takanashi; Yasuhiro Egi; Ryou Tatsumi
Journal of Medicinal Chemistry | 2006
Ryo Tatsumi; Masakazu Fujio; Shinichi Takanashi; Atsushi Numata; Jiro Katayama; Hiroyuki Satoh; Yasuyuki Shiigi; Junichi Maeda; Makoto Kuriyama; Takashi Horikawa; Takahiro Murozono; Kenji Hashimoto; Hiroshi Tanaka
Archive | 1999
Takanobu Kuroita; Masakazu Fujio; Haruto Nakagawa
Journal of Medicinal Chemistry | 2005
Ryo Tatsumi; Masakazu Fujio; Hiroyuki Satoh; Jiro Katayama; Shinichi Takanashi; Kenji Hashimoto; Hiroshi Tanaka
Archive | 1997
Takanobu Kuroita; Yoshifumi Togo; Seigo Ishibuchi; Masakazu Fujio; Takashi Futamura
Archive | 2000
Masakazu Fujio; Kenji Hashimoto; Jiro Katayama; Atsushi Numata; 謙二 橋本; 敦 沼田; 二郎 片山; 雅和 藤尾
Archive | 2001
Masakazu Fujio; Kenji Hashimoto; Jiro Katayama; Atsushi Numata